Calavo Growers (NASDAQ:CVGW) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.33 by 90.91 percent. This is a 137.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $243.57 million which missed the analyst consensus estimate of $297.97 million by 18.26 percent. This is a 10.92 percent decrease over sales of $273.42 million the same period last year.
Mirati Therapeutics And Aadi Bioscience Partner To Evaluate The Combination Of Adagrasib With Nab-sirolimus In Patients With Advanced Non-Small Cell Lung Cancer And Other Solid Tumors With A KRAS[G12C] Mutation
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial stage biopharmaceutical company focused on developing and commercializing
